NasdaqCM:SLSBiotechs
Assessing SELLAS Life Sciences Group (SLS) Valuation After New Phase 3 REGAL Trial Progress News
SELLAS Life Sciences Group (SLS) is back in focus after new clinical data from its Phase 3 REGAL trial and an independent committee’s decision to keep the study running without changes.
See our latest analysis for SELLAS Life Sciences Group.
The recent clinical updates appear to be feeding into strong momentum, with a 30 day share price return of 26.92% and a 90 day share price return of 203.45%, while the 1 year total shareholder return of 343.70% contrasts with a weaker 5 year total...